Liver Cancer

218

Pipeline Programs↗

51

Active Trials↗

81

Companies Involved↗

Liver Cancer is a highly competitive landscape with 218 programs across 81 companies. The most active players are Boehringer Ingelheim, Binhui Biopharmaceutical Co., Ltd., CNBG-Virogin Biotech (Shanghai) Ltd.. 12 therapies are approved with 41 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

82/100

Pipeline Velocity

36/100

Mech. Concentration

5/100

Completion Rate

74/100

Attrition Rate

17/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Boehringer Ingelheim

2 programs

Binhui Biopharmaceutical Co., Ltd.

1 program

CNBG-Virogin Biotech (Shanghai) Ltd.

1 program

Acrotech Biopharma Inc.

1 program

Moderna

1 program

Amgen

1 program

Pipeline

Programs by Phase

Preclinical19

Indocyanine Green

CHX Technologies Inc.

Lidocaine Hydrochloride

Citius Pharmaceuticals, Inc.

Ipilimumab

Bristol-Myers Squibb

Propofol

Fresenius Kabi Oncology Ltd.

Ciprofol

Haisco Pharmaceutical Group Co., Ltd.

Phase 138

Sargramostim

Sanofi

Belinostat

Acrotech Biopharma Inc.

LY3287104

Eli Lilly

Ezabenlimab

Boehringer Ingelheim

Mrna-5671

Moderna

Phase 2108

Irinotecan Hydrochloride

Eastern Cooperative Oncology Group

Dostarlimab

Glaxo Dba Glaxosmithkline

Lapatinib Ditosylate

Novartis

Antineoplaston A10

Burzynski Research Institute

Alvocidib

Sumitomo Pharma America, Inc.

Phase 341

Megestrol Acetate

Bristol-Myers Squibb

Tivantinib

Daiichi Sankyo

BMS-986205

Bristol-Myers Squibb

Carboplatin

Avyxa

Tremelimumab

AstraZeneca

Approved12

Carmustine

Melissa K Accordino

Paclitaxel

Teva

Bleomycin

Bristol-Myers Squibb

Pemetrexed

Eagle Vision Pharmaceutical Corp.

Lenalidomide

Karuna Therapeutics, Inc., a Bristol Myers Squibb company

Analysis

Modality Breakdown

81%

Small molecule

185 of 227 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 227 classified programs, each share of the total. Modality classified for 100% of 262 pipeline programs.

Analysis

Trial Status

266

clinical trials

Completed129 · 48%

Unknown status41 · 15%

Terminated34 · 13%

Recruiting27 · 10%

Active, not recruiting14 · 5%

Not yet recruiting10 · 4%

Other11 · 4%

Clinical Trials

Trial Activity

266 trials

AU409 for the Treatment of Advanced Primary Liver Cancers or Solid Tumor With Liver Metastatic Disease

Recruiting·UUniversity of Southern California·Phase 1·NCT05791448·36 enrolled

Celecoxib, Durvalumab and Tremelimumab for the Treatment of Patients With Advanced or Metastatic Liver Cancer

Recruiting·EEmory University·Phase 2·NCT07174570·39 enrolled

Clinical Study of VG161 in Subjects with Advanced Primary Liver Cancer

Recruiting·CCNBG-Virogin Biotech (Shanghai) Ltd.·Phase 1·NCT04806464·44 enrolled

Ligufalimab and Cadonilimab in Advanced Liver Cancers

Recruiting·UUniversity of Texas Southwestern Medical Center·Phase 2·NCT06789848·64 enrolled

CXD101 in Immunotherapy-related Liver Cancer

Recruiting·—·Phase 2·NCT05873244·44 enrolled

China Liver Cancer Clinical Registry Cohort Database (HEAL)

Recruiting·—·N/A·NCT06777485·10,000 enrolled

Nimotuzumab Combined With ICIs for the Treatment of Advanced Liver Cancer After First Line Treatment Failure

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT06413017·30 enrolled

OH2 Oncolytic Viral Therapy Via Transcatheter Intraarterial Infusion in Patients with Advanced Liver Cancer

Recruiting·BBinhui Biopharmaceutical Co., Ltd.·Phase 1·NCT05698459·12 enrolled

18F-FSPG PET in Imaging Patients With Liver Cancer Before Undergoing Surgery or Transplant

Recruiting·MM.D. Anderson Cancer Center·Phase 1·NCT02379377·110 enrolled

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Advanced Liver Cancer

Recruiting·—·Phase 1·NCT06084299·16 enrolled

The Efficacy of Sequential Treatment With Bevacizumab Combined With Atezolizumab in Advanced Liver Cancer With MASLD

Recruiting·—·Phase 2/3·NCT07285850·20 enrolled

Selective Internal Radiation Therapy and Capecitabine (Chemotherapy) Treatment for Liver Cancer

Recruiting·CCenter Eugene Marquis·Phase 2·NCT05265208·62 enrolled

Lenvatinib Plus Sintilimab in Patients With Immune Checkpoint Inhibitor Previously Treated Advanced Liver Cancer

Recruiting·FFudan University·Phase 2·NCT05010681·25 enrolled

A Pilot Study on the Effect of Cannabis Oil in Untreatable Liver Cancer Patients

Recruiting·UUniversity Medical Center Groningen·Phase 2·NCT06518434·20 enrolled

Fecal Microbiota Transfer in Liver Cancer to Overcome Resistance to Atezolizumab/Bevacizumab (FLORA)

Recruiting·—·Phase 2·NCT05690048·48 enrolled

Page 1 of 18

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)